DDrare: Database of Drug Development for Rare Diseases

All subjects will receive maraviroc 300mg orally twice a day for 6 weeks (DrugBank: Maraviroc)

告示番号	疾患名（ページ内リンク）	臨床試験数
84	サルコイドーシス	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02134717 (ClinicalTrials.gov)	January 2014	30/4/2014	Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes	An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis	Sarcoidosis	Drug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsy	Kevin F. Gibson	University of Pittsburgh	Terminated	18 Years	80 Years	All	3	N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02134717
(ClinicalTrials.gov)

January 2014

30/4/2014

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis

Sarcoidosis

Drug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsy

Kevin F. Gibson

University of Pittsburgh

Terminated

18 Years

80 Years

All

N/A

United States